Upgrade to SI Premium - Free Trial

Mizuho Downgrades Sarepta Therapeutics (SRPT) to Neutral

July 21, 2025 4:33 AM
Mizuho analyst Uy Ear downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform to Neutral with a price target of $14.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades

Next Articles